Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 228.13M |
| Revenue (ttm) | 1.55M |
| Net Income (ttm) | -63.06M |
| Shares Out | 122.65M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 471,142 |
| Open | 1.860 |
| Previous Close | 1.860 |
| Day's Range | 1.860 - 1.895 |
| 52-Week Range | 1.000 - 3.060 |
| Beta | 0.69 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+330.11%) |
| Earnings Date | May 13, 2026 |
About MIST
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Ph... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for MIST stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 330.11% from the latest price.
News
Milestone Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
CARDAMYST launched as the first new PSVT treatment in decades, offering rapid, at-home relief and strong clinical data. The company is targeting 10,000 key providers with 60 sales reps, secured initial payer coverage, and is advancing a phase III trial for AFib-RVR, supported by $200M in cash and a clear path to break-even.
Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST™ (etripamil) Nasal Spray in Patients With PSVT
Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium Registry Study Design Presented at the Preventive Cardiovascular Nurses Associ...
Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
MONTREAL and CHARLOTTE, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovati...
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., April 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, i...
Milestone Pharmaceuticals Announces that CARDAMYST™ (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies
MONTREAL and CHARLOTTE, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Why Milestone Pharma Stock Is Taking A Dive Today
Milestone Pharmaceuticals Inc. (NASDAQ:MIST) shares are tumbling on Friday after the company revealed a minor pushback in European approval for its lead drug.
Milestone Pharmaceuticals Earnings Call Transcript: Q4 2025
FDA approval and U.S. launch of CARDAMYST marked a pivotal year, with strong initial prescription activity and a robust $200 million cash position supporting operations into late 2027. Early payer coverage is limited, but commercial and Medicare access are expected to expand in 2026–2027.
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT
MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) will release earnings for its fourth quarter before the opening bell on Thursday, March 19.
Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session
MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report fourth quarter and full-year 2025 results and provid...
Milestone Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
CARDAMYST, a novel nasal spray for PSVT, launched with strong commercial support and no branded competition, targeting 2 million US patients. Early uptake is promising, with expansion plans for atrial fibrillation and ex-US markets via partnerships.
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Comme...
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance ...
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially insure...
Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency
European decision on approval is expected by Q1 2027 If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the he...
Milestone Pharmaceuticals Transcript: FDA Announcement
FDA approved Cardamyst nasal spray for PSVT, marking the first new therapy in over 30 years. The product demonstrated rapid efficacy, a strong safety profile, and is expected to reduce emergency visits. Launch plans target key cardiology providers, with broad access and support programs in place.
Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT enab...
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
PDUFA Target Date of December 13, 2025 for CARDAMYST™ (etripamil) Nasal Spray in Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025
Data show consistent efficacy, safety, and tolerability findings across multiple clinical trials that evaluated self-administered etripamil Data show consistent efficacy, safety, and tolerability find...
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
MONTREAL and CHARLOTTE, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovativ...
Milestone Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Etripamil (Cardamyst) targets a large SVT market with FDA approval expected by year-end. Launch plans focus on retail access, affordable pricing, and payer engagement, with a staged rollout and strong physician adoption anticipated.
Milestone® Pharmaceuticals to Present at Upcoming Conferences
MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings a...
Milestone Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
FDA Accepted the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray; New PDUFA Target Date of December 13, 2025
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index dipping more than 250 points on Friday.